A Clearance Period after Soluble Lead Nanoparticle Inhalation Did Not Ameliorate the Negative Effects on Target Tissues Due to Decreased Immune Response

Int J Mol Sci. 2020 Nov 19;21(22):8738. doi: 10.3390/ijms21228738.

Abstract

The inhalation of metal (including lead) nanoparticles poses a real health issue to people and animals living in polluted and/or industrial areas. In this study, we exposed mice to lead(II) nitrate nanoparticles [Pb(NO3)2 NPs], which represent a highly soluble form of lead, by inhalation. We aimed to uncover the effects of their exposure on individual target organs and to reveal potential variability in the lead clearance. We examined (i) lead biodistribution in target organs using laser ablation and inductively coupled plasma mass spectrometry (LA-ICP-MS) and atomic absorption spectrometry (AAS), (ii) lead effect on histopathological changes and immune cells response in secondary target organs and (iii) the clearance ability of target organs. In the lungs and liver, Pb(NO3)2 NP inhalation induced serious structural changes and their damage was present even after a 5-week clearance period despite the lead having been almost completely eliminated from the tissues. The numbers of macrophages significantly decreased after 11-week Pb(NO3)2 NP inhalation; conversely, abundance of alpha-smooth muscle actin (α-SMA)-positive cells, which are responsible for augmented collagen production, increased in both tissues. Moreover, the expression of nuclear factor κB (NF-κB) and selected cytokines, such as tumor necrosis factor alpha (TNFα), transforming growth factor beta 1 (TGFβ1), interleukin 6(IL-6), IL-1α and IL-1β , displayed a tissue-specific response to lead exposure. In summary, diminished inflammatory response in tissues after Pb(NO3)2 NPs inhalation was associated with prolonged negative effect of lead on tissues, as demonstrated by sustained pathological changes in target organs, even after long clearance period.

Keywords: LA-ICP-MS imaging; clearance; inhalation; lead nanoparticles; toxicity.

MeSH terms

  • Actins / agonists
  • Actins / genetics
  • Actins / immunology
  • Administration, Inhalation
  • Air Pollutants / pharmacokinetics*
  • Air Pollutants / toxicity
  • Animals
  • Biological Availability
  • Female
  • Gene Expression
  • Half-Life
  • Inhalation Exposure / analysis
  • Interleukin-1alpha / agonists
  • Interleukin-1alpha / genetics
  • Interleukin-1alpha / immunology
  • Interleukin-1beta / agonists
  • Interleukin-1beta / genetics
  • Interleukin-1beta / immunology
  • Interleukin-6 / agonists
  • Interleukin-6 / genetics
  • Interleukin-6 / immunology
  • Lead / pharmacokinetics*
  • Lead / toxicity
  • Liver / drug effects
  • Liver / immunology
  • Liver / pathology
  • Lung / drug effects*
  • Lung / immunology
  • Lung / pathology
  • Macrophages, Alveolar / drug effects*
  • Macrophages, Alveolar / immunology
  • Macrophages, Alveolar / pathology
  • Metal Nanoparticles / administration & dosage
  • Metal Nanoparticles / toxicity*
  • Mice
  • Mice, Inbred ICR
  • NF-kappa B / agonists
  • NF-kappa B / genetics
  • NF-kappa B / immunology
  • Nitrates / pharmacokinetics*
  • Nitrates / toxicity
  • Spectrophotometry, Atomic
  • Tissue Distribution
  • Transforming Growth Factor beta1 / agonists
  • Transforming Growth Factor beta1 / genetics
  • Transforming Growth Factor beta1 / immunology
  • Tumor Necrosis Factor-alpha / agonists
  • Tumor Necrosis Factor-alpha / genetics
  • Tumor Necrosis Factor-alpha / immunology

Substances

  • Actins
  • Air Pollutants
  • IL1B protein, mouse
  • Il1a protein, mouse
  • Interleukin-1alpha
  • Interleukin-1beta
  • Interleukin-6
  • NF-kappa B
  • Nitrates
  • Tgfb1 protein, mouse
  • Transforming Growth Factor beta1
  • Tumor Necrosis Factor-alpha
  • alpha-smooth muscle actin, mouse
  • interleukin-6, mouse
  • Lead
  • lead nitrate